KRAS and colorectal carcinoma: The results showed that the most common mutations were APC (81 %), TP53 (63 %), TTN (47 %), KRAS (44 %), SYNE1 (29 %), PIK3CA (25 %), MUC16 (23 %), FAT4 (20 %), OBSCN (20 %), and RYR2 (20 %) in male CRC patients (Fig. 2A).